Aradigm Informed Investor Conference presentation (Archived 2000)
•Download as PPTX, PDF•
1 like•1,760 views
This presentation discusses Aradigm Corporation, a leader in pulmonary drug delivery technology. It highlights the benefits of its AERx pulmonary delivery system, including fast onset and non-invasive administration. Aradigm has several drug programs in development through partnerships with major pharmaceutical companies. These include Phase 2 programs for insulin, morphine, and dornase alfa. The presentation outlines Aradigm's business model and developmental milestones expected in 2000-2001.
Aradigm Informed Investor Conference presentation (Archived 2000)
- 2. This presentation, and its accompanying commentary, contains forward-looking statements.Aradigm Corporation’s actual results may differ materially from those suggested here today. Additional information concerning factors that would cause such a difference is contained in the Company’s 1999 Annual Report on Form 10-K.Aradigm Corporation
- 3. Aradigm at a GlanceA Leader in Pulmonary Drug DeliveryTechnology platform is applicable to many therapeutic areasPartnered with industry leadersNovo Nordisk, SmithKline Beecham and Genentech$55M invested to dateAERx hand-held device is convenient, simple to use and designed to prevent errors in dosing
- 4. Benefits of AERx Pulmonary DeliveryTime to peak morphine concentration as fast as intravenous injectionFaster reduction of glucose levels with insulin than with injection90% reduction in dosing time in Cystic FibrosisAchieves therapeutic levels of biotech drugs,non-invasively
- 5. Advanced Pulmonary Drug DeliveryAdvantagesLarge Surface AreaNear Direct AccessNatural FunctionBenefitsNon-invasiveFast onsetBroad applicability
- 6. Nozzle AreaBlister AreaAERx Particle Size ControlConsistently small particles (1-3 microns)Point-of-use aerosol controlSingle use, disposable
- 7. AERx Control of Patient InhalationDevice actively guides patient to breathe correctlyAutomatically delivers drug at right timeEliminates patient breathing as a source of error
- 9. Liquid formulationFast developmentUnit dose disposable packetSuperior aerosol performanceBreath controlConsistent dose deliveryData captureEnhances therapy complianceThe AERx Advantage
- 10. Local Lung DeliverySystemic DeliveryPulmonary Delivery ApplicationsUndisclosed Phase IMorphine-Phase IIUndisclosed-Phase ISmall MoleculeInsulin-Phase IIGene Therapy-preclinicalUndisclosed-preclinicalDornase alfa-Phase IIUndisclosed-Phase IIGene Therapy-preclinicalMacro-moleculeThe most broadly applicable technology
- 11. Eight partner funded programs
- 12. Four phase II programsLeading Partner Endorsements AERx Diabetes Management SystemAERx Pain Management SystemAERx Respiratory Management SystemPlus five more unannounced programs
- 14. Diabetes Management RequirementsAERx Diabetes Management SystemAchieve ReproducibilityTight control over particle size and breathingAdjustable DosingOne insulin unit incrementsAccess to InsulinNovo Nordisk is the world leader in insulin
- 16. Pain Management RequirementsAERx Pain Management SystemRapid, ReproducibleComparable to intravenous deliveryMinimize Misuse & AbuseTimed lockouts and secure accessAccess to Oncology/Pain MarketSmithKline Beecham has a growing oncology franchise
- 18. Cystic Fibrosis Management RequirementsAERx System with Dornase AlfaFast and Simple90% reduction in dosing timeImproved Adherence with TherapyConvenience and electronic compliance monitoringAccess to CF MarketGenentech is a leader in Cystic Fibrosis therapy
- 19. Most biotech drugs are in stable liquid formulationsAERx Well Positioned for Future OpportunitiesChronic bronchitis and emphysema drugsAntibodiesGene therapiesAsthma drugsHematopoetic factorsHuman growth factorsAnti-obesity drugsMigraine drugsAnti-Parkinson’s drugsInterleukinsInterferonsAntibiotics
- 20. DevelopmentManufacturingCommercial SalesAradigm Business Model- Pharma Profitability...Partner pays costs10%-25% ofproduct sales40%-60% gross marginsARDM receives transfer price profitARDM receives royalty…But With Lower Risk Profile
- 22. Cash Summary
- 23. 2000 / Early 2001 MilestonesAdvances in intellectual property positionPhase II insulin data at American Diabetes Association meeting (June 2000)Potential feasibility and long-term partnershipsInitiation of Phase IIb morphineInitiation of Phase IIb dornase alfaInitiation of pivotal insulin studies